A triple transgenic murine model for AD (3xTg-AD) has been utilized for AD studies. The 3xTg-AD murine model exhibits plaque and tangle pathology,
47 as well as synaptic dysfunction.
48 The onset of Aβ and tau plaques for 3xTg-AD is similar to that of AD in human patients, both age- and region-dependent.
49,50 For the 3xTg-AD murine model, Aβ immunoreactivity has been observed at 2 months in the hippocampus.
50 At 4 months, intraneuronal Aβ pathology is visible in the cortex and amygdala
51 and correlates with observable cognitive deficits.
52 At month 6, Aβ deposits are observed in the frontal cortex,
51 together with the appearance of learning deficits, memory impediments, and neophobia.
53 At 12 months, Aβ are present in the hippocampus and other cortical regions,
53 and tau immunoreactivity becomes apparent in pyramidal neurons in the CA1 region.
51
Many AD pathologies are present in the retina (an anterior extension of the central nervous system) at varying ages in the 3xTg-AD model. In one study, retinal thickness decreased significantly, but Aβ was not detected at 4 or 8 months, although the tau levels were elevated.
54 In another study, profound tau pathology was observed in the visual system in 3xTg-AD animals as early as 3 months, prior to observation of behavioral deficits and tau accumulation in the brain.
55 The tau build-up occurred mostly in the soma and dendrites of the retinal ganglion cells (RGCs); tau depletion occurred primarily in RGC axons and the optic nerve. The morphology of Müller cells and astrocytes was examined in the 3xTg-AD retina and found to undergo complex remodeling similar to astrocyte changes in the mouse brain. Cordeiro et al.
56 showed that 14-month-old 3xTg-AD mice showed significantly more RGCs in the early stages of apoptosis and fewer necrotic cells compared to age-matched controls.